Clinical trial tests combination therapy in untreated aggressive B-cell lymphomas

lymphoma cells

Human lymphoma tumor cells in the pleural fluid stained with a Defquick stain and magnified to 400x.
Photo courtesy of NCI Visuals Online

Patients with untreated aggressive B-cell lymphomas may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Aggressive B-cell lymphomas are a cancer that starts in white blood cells called lymphocytes. B-cell lymphomas usually grows in lymph nodes, the pea-sized glands clustered along the lymphatic system, but can occur in other areas of the body. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch, is leading a study of a combination therapy using a drug that interferes with the activity of an enzyme that plays a crucial role in the development of B cells and in the cellular signaling that allows cancerous cells to multiply and survive. Investigators aim to see if this drug, in addition to standard B-cell lymphomas therapies, can improve response rates in patients.

Clinicaltrials.gov identifier: NCT04002947
NCI Protocol ID: NCI-19-C-0116
Official Title: A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.   

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Thu, 08/22/2019